抗癌药物的最新进展。
Recent Advances in Anti-Cancer Drugs.
作者信息
Neophytou Christiana M
机构信息
Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus.
出版信息
Int J Mol Sci. 2025 Aug 30;26(17):8446. doi: 10.3390/ijms26178446.
Abstract
Despite the significant advancements in anti-cancer research in the last two decades, the development of anti-cancer therapeutics remains a central focus in oncology [...].
摘要
尽管在过去二十年里抗癌研究取得了重大进展，但抗癌治疗方法的开发仍然是肿瘤学的核心焦点[...]。
相似文献
1
Recent Advances in Anti-Cancer Drugs.抗癌药物的最新进展。
Int J Mol Sci. 2025 Aug 30;26(17):8446. doi: 10.3390/ijms26178446.
2
Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology.油橄榄苦素作为一种多功能抗癌剂：作用机制见解、先进递送策略及精准肿瘤学中的协同作用
Int J Mol Sci. 2025 Jun 9;26(12):5521. doi: 10.3390/ijms26125521.
3
Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment.表观遗传疗法与靶向蛋白质降解相结合：癌症治疗中的组蛋白去乙酰化酶-蛋白酶体靶向嵌合体
Future Med Chem. 2025 Jul 16:1-13. doi: 10.1080/17568919.2025.2533113.
4
MicroRNA nanoformulation: a promising approach to anti-tumour activity.微小RNA纳米制剂：一种有前景的抗肿瘤活性方法。
Invest New Drugs. 2025 May 14. doi: 10.1007/s10637-025-01534-7.
5
Quality of Animal Experiments in Anti-Angiogenic Cancer Drug Development--A Systematic Review.抗血管生成抗癌药物研发中动物实验的质量——一项系统评价
PLoS One. 2015 Sep 30;10(9):e0137235. doi: 10.1371/journal.pone.0137235. eCollection 2015.
6
Combination therapy in combating cancer.癌症治疗中的联合疗法。
Oncotarget. 2017 Jun 6;8(23):38022-38043. doi: 10.18632/oncotarget.16723.
7
Artificial Intelligence-Driven Innovations in Oncology Drug Discovery: Transforming Traditional Pipelines and Enhancing Drug Design.人工智能驱动的肿瘤学药物发现创新：变革传统流程并优化药物设计
Drug Des Devel Ther. 2025 Jul 3;19:5685-5707. doi: 10.2147/DDDT.S509769. eCollection 2025.
8
Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.癌症治疗相关的 QT 间期延长的发生率、诊断和处理：系统评价。
J Am Heart Assoc. 2017 Dec 7;6(12):e007724. doi: 10.1161/JAHA.117.007724.
9
Transferrin-guided liposomal nanocarriers: A strategy for targeted cancer treatment.转铁蛋白导向脂质体纳米载体：一种靶向癌症治疗的策略。
Int J Biol Macromol. 2025 Jun 20;319(Pt 3):145377. doi: 10.1016/j.ijbiomac.2025.145377.
10
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy.挖掘潜在可能：药物重用于癌症治疗的进展、方法和障碍。
Br J Cancer. 2024 Mar;130(5):703-715. doi: 10.1038/s41416-023-02502-9. Epub 2023 Nov 27.
本文引用的文献
1
Genetic landscape of cancer: mechanisms, key genes, and therapeutic implications.癌症的遗传图谱：机制、关键基因及治疗意义。
Clin Transl Oncol. 2025 Aug 17. doi: 10.1007/s12094-025-04019-4.
2
Tumor Microenvironment: A Complex Landscape of Cancer Development and Drug Resistance.肿瘤微环境：癌症发展与耐药性的复杂图景
Cureus. 2025 Apr 11;17(4):e82090. doi: 10.7759/cureus.82090. eCollection 2025 Apr.
3
Emerging Strategies of Cell and Gene Therapy Targeting Tumor Immune Microenvironment.靶向肿瘤免疫微环境的细胞和基因治疗新策略
Clin Cancer Res. 2025 Jun 13;31(12):2294-2308. doi: 10.1158/1078-0432.CCR-24-4308.
4
The mechanopathology of the tumor microenvironment: detection techniques, molecular mechanisms and therapeutic opportunities.肿瘤微环境的机械病理学：检测技术、分子机制与治疗机遇
Front Cell Dev Biol. 2025 Mar 18;13:1564626. doi: 10.3389/fcell.2025.1564626. eCollection 2025.
5
Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics.一组高级别浆液性卵巢癌患者中TP53突变与铂耐药性之间的关联：对个性化治疗的新启示。
Int J Mol Sci. 2025 Mar 1;26(5):2232. doi: 10.3390/ijms26052232.
6
Targeting Tumor Microenvironment Interactions in Chronic Lymphocytic Leukemia Using Leukotriene Inhibitors.使用白三烯抑制剂靶向慢性淋巴细胞白血病中的肿瘤微环境相互作用
Int J Mol Sci. 2025 Feb 28;26(5):2209. doi: 10.3390/ijms26052209.
7
Comprehensive Bioinformatics Analysis of Glycosylation-Related Genes and Potential Therapeutic Targets in Colorectal Cancer.结直肠癌中糖基化相关基因及潜在治疗靶点的综合生物信息学分析
Int J Mol Sci. 2025 Feb 14;26(4):1648. doi: 10.3390/ijms26041648.
8
Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization.携带Her2扩增和KRAS异常定位的KRAS突变型结直肠癌中KRAS抑制剂耐药的机制。
NPJ Precis Oncol. 2025 Jan 6;9(1):4. doi: 10.1038/s41698-024-00793-6.
9
KRAS inhibitors: resistance drivers and combinatorial strategies.KRAS抑制剂：耐药驱动因素与联合策略
Trends Cancer. 2025 Feb;11(2):91-116. doi: 10.1016/j.trecan.2024.11.009. Epub 2024 Dec 27.
10
The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives.肿瘤微环境在胰腺癌免疫治疗中的作用：现状与未来展望。
Int J Mol Sci. 2024 Sep 3;25(17):9555. doi: 10.3390/ijms25179555.
Zotero 插件